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Résumé en
anglais
Small cell lung cancer (SCLC) is the most aggressive carcinoma in thoracic
oncology, unfortunately, despite chemotherapy, relapse is constant. The effect of
etoposide, a major drug used against SCLC, can potentially be enhanced after its
encapsulation in nanocarriers. The aim of this study was to use the technology of
lipid nanocapsules (LNCs) to obtain nanocarriers with drug loadings compatible
with clinical use and with an industrial process. Solubility studies with different co-
solvent were first performed, then several process were developed to obtain LNCs.
LNCs were then characterized (size, zeta potential, and drug loading). The best
formulation called Ω-LNCs had a size of 54.1±2.0 nm and a zeta potential of
-5.8±3.5 mV and a etoposide drug loading of 5.7±0.3mg/g. The characteristics of
this formulation were maintained after freeze drying and after a 15× scale-up.
Release studies in a media mimicking plasma composition showed that 40% of the
drug was released from the LNCs after 48 h. Moreover the activity of etoposide after
encapsulation was enhanced on H209 cells, IC50 was 100 μM and 2.5 μM for
etoposide and etoposide LNCs respectively. Unfortunately the formulation failed to
be more cytotoxic than etoposide alone on H69AR cells that are resistant to
etoposide. This study showed that is was possible to obtain a new etoposide
nanocarrier without the use of organic solvent, that the process is suitable for scale-
up and freeze drying and finally that etoposide activity is maintained which is very
promising for future treatment of SCLC.
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